Whether the potentiation of COX-2 promoted activities by taxanes could influence the overall sensitivity of ovarian cancer cells to the combination platinum/paclitaxel, by conceivably reducing the favourable impact of paclitaxel addition, remains to be verified. The gene discussed is PTGS2; the disease is ovarian cancer.